The faculty of Department of Studies in Microbiology in the Karnataka State Open University (KSOU) in Mysuru has performed a key role in the development of an Artificial Intelligence (AI)-driven device for detection of early indicators of cardiovascular stress.
The MyoBioScan device, developed by Ravichandra Mulpuri, an Indian-origin researcher based mostly in the US, is a non-invasive and diagnostic software geared toward enabling real-time monitoring of cardiovascular health. By capturing and analysing delicate physiological adjustments, the device, described as a “wearable patch”, seeks to alert customers to potential heart-related points earlier than they grow to be life threatening.
The MyoBioScan, whichhas been featured in the April-June 2025 challenge of the International Journal on Science and Technology (IJSAT), is in its prototype and validation stage. “The device integrates multi-channel ECG acquisition with sweat-based biochemical sensing for key cardiac biomarkers”.
The developer, Mr. Mulpuri, was guided nearly by consultants from the KSOU, viz. Niranjan Raj and Syed Baker, who chosen and validated the suitable biomarkers for cardiovascular health monitoring.
The device, ideally worn throughout workout routines like operating or coaching in the fitness center, will analyse the individual’s sweat for numerous hormones and protein complexes that function cardiovascular biomarkers, mentioned Mr. Baker.
“The sweat-based biomarkers like troponin-I, NT-proBNP, lactate, cortisol, and pH, provide an insight into cardiovascular health,” he mentioned. The KSOU faculty’s educational mentorship was instrumental in shaping the scientific spine of MyoBioScan, enhancing each its scientific relevance and technical design.
The device has been designed to provide three alerts based mostly on its evaluation. “Normal — keep monitoring, consult a medical professional, and emergency,” he mentioned.
Quoting Mr. Mulpuri, Mr. Baker mentioned that the device had the potential to grow to be a low-cost, accessible diagnostic software that may rework how early cardiovascular dangers may be detected and managed.
The summary of MyoBioScan in IJSAT mentioned a pilot research evaluated the device for its efficiency in 80 members, together with wholesome people and people with recognized circumstances equivalent to atrial fibrillation, myocardial ischemia, and early-stage coronary heart failure.
“Subclinical abnormalities were detected in 4 asymptomatic individuals and confirmed through clinical follow-up. Sweat biomarker levels significantly differed between healthy and stressed participants, showing strong correlation with laboratory standards. User feedback revealed high satisfaction in terms of comfort, clarity of app feedback and trust in results, with over 90% expressing interest in long-term use,” the summary mentioned.
